Vaxcell-Bio Therapeutics Past Earnings Performance
Past criteria checks 0/6
Vaxcell-Bio Therapeutics's earnings have been declining at an average annual rate of -35.8%, while the Biotechs industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 171.8% per year.
Key information
-35.8%
Earnings growth rate
-7.7%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 171.8% |
| Return on equity | -12.3% |
| Net Margin | -74,865.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How Vaxcell-Bio Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 14 | -10,274 | 6,171 | 4,919 |
| 30 Sep 23 | 0 | -9,689 | 6,765 | 4,103 |
| 30 Jun 23 | 0 | -8,554 | 6,559 | 3,256 |
| 31 Mar 23 | 0 | -7,383 | 6,078 | 2,515 |
| 31 Dec 22 | 0 | -6,825 | 5,793 | 2,075 |
| 30 Sep 22 | 0 | -6,039 | 4,711 | 2,171 |
| 30 Jun 22 | 0 | -5,667 | 4,467 | 1,868 |
| 31 Mar 22 | 0 | -5,672 | 4,366 | 1,852 |
| 31 Dec 21 | 0 | -4,763 | 3,811 | 1,810 |
| 30 Sep 21 | 0 | -4,482 | 3,355 | 1,758 |
| 30 Jun 21 | 0 | -4,059 | 2,883 | 1,663 |
| 31 Mar 21 | 0 | -3,597 | 2,553 | 1,501 |
| 31 Dec 20 | 0 | -3,984 | 2,714 | 1,350 |
| 30 Sep 20 | 0 | -3,959 | 2,821 | 987 |
Quality Earnings: A323990 is currently unprofitable.
Growing Profit Margin: A323990 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A323990 is unprofitable, and losses have increased over the past 5 years at a rate of 35.8% per year.
Accelerating Growth: Unable to compare A323990's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A323990 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (28.8%).
Return on Equity
High ROE: A323990 has a negative Return on Equity (-12.31%), as it is currently unprofitable.